Carnitine palmitoyltransferase 1A deficiency (CPT1A)
Log in to starLast updated Nov 4, 2026
An infant of Inuit ancestry presents with hypoketotic hypoglycemia, hepatomegaly, and elevated transaminases after a viral illness. Newborn screening flagged a very high C0 (free carnitine) with low long-chain acylcarnitines.
AR; CPT1A (carnitine palmitoyltransferase 1A, the liver and kidney isoform on the outer mitochondrial membrane). Biallelic variants that reduce its expression or activity block long-chain fat entry into liver mitochondria.
CPT1A converts long-chain acyl-CoAs to acylcarnitines on the outer mitochondrial membrane, the first and rate-limiting step of the carnitine shuttle. In the liver, this step lets fatty acids fuel ketogenesis once glycogen runs low during fasting or illness, which feeds tissues that cannot oxidize fat themselves.
Loss of CPT1A function, from lost mRNA expression or reduced enzyme activity, gives fasting intolerance: hypoketotic hypoglycemia, raised transaminases, and sometimes hyperammonemia. The isoform is also expressed in kidney, which explains renal tubular acidosis. Heart and skeletal muscle rely on a different isoform (CPT1B), so cardiac and muscle disease are uncommon, unlike other long-chain defects. Because acylcarnitines cannot form, all acylcarnitine species are low and free carnitine (C0) is high.
Founder variants differ in effect. The Inuit variant p.Pro479Leu leaves partial activity: most homozygotes never have symptoms, but infants have impaired fasting tolerance and higher infant mortality, and acylcarnitine screening often misses them. The Hutterite variant p.Gly710Glu causes typical disease in early childhood. Medium-chain fats bypass the shuttle, which is why MCT is used.
Part of the carnitine shuttle.
Carnitine shuttle, the first step, which gates long-chain fat entry into mitochondria.
long-chain fatty acyl-CoA in the cytosol, with free carnitine → CPT1A, outer mitochondrial membrane (the block) → long-chain acylcarnitine → CACT → CPT2 → long-chain acyl-CoA in the matrix → beta-oxidation → acetyl-CoA → ketone bodies
- Accumulates: free carnitine, measured as high C0 with a high C0/(C16+C18) ratio.
- Missing: long-chain acylcarnitines (all species low) and hepatic ketogenesis during fasting, so glucose falls without ketones.
- Workbook: 5.D. Disorders of the carnitine shuttle system
- Hepatic-only phenotype: hypoketotic hypoglycemia, hepatomegaly, transaminitis during fasting or illness
- No cardiomyopathy and no skeletal myopathy (the muscle isoform is intact)
- Renal tubular acidosis can occur
- On RUSP
- Newborn screening (RUSP) acylcarnitine profile: high free carnitine (C0) with low long-chain acylcarnitines, giving an elevated C0/(C16+C18) ratio (the signature, opposite of carnitine uptake defect)
- Reduced CPT1 enzyme activity in cultured fibroblasts
- Confirmatory CPT1A molecular testing (founder variants: c.1436C>T, p.Pro479Leu in Inuit and other Arctic populations, often missed by acylcarnitine screening alone; c.2129G>A, p.Gly710Glu in Hutterites)
- Avoid fasting; emergency IV dextrose during illness
- MCT-rich diet is well tolerated (medium-chain fats bypass CPT1)
NBS: high C0, low long-chain acylcarnitines. The opposite of carnitine uptake defect (which has low C0). CPT1 sits at the entrance to the mitochondrion; when it fails, free carnitine piles up outside while long-chain acylcarnitines cannot form. High C0/(C16+C18) ratio is the diagnostic signature.
"1 is for the liver": CPT1A is the liver isoform, so the phenotype is liver-dominant (hepatomegaly, hypoglycemia) without the cardiac or muscle involvement seen in CPT2 or CACT.